See other companies on Welcome to the Jungle
myTomorrows
Platform for discovering and accessing treatments in development
- 21-100 employees
- Healthcare
- B2C
- B2B
- Personal health
- Biology
- SaaS
- Social Impact
- Hoofddorppleinbuurt, Amsterdam, NH
Jump to section
Company mission
To help patients discover and access all possible treatment options.
Our take
In Europe alone there are around 1 million patients with debilitating diseases who have few or no treatment options for their conditions. For many, experimental drugs may hold the key to effective treatment, but an alarming 95% of such patients will not meet the eligibility criteria to enter clinical trials for these potentially life-improving medications. For patients who cannot wait for new drugs to become fully approved and available, it has historically been very difficult to access treatments in development.
This is what myTomorrows has set out to change. Founded in 2012, myTomorrows is a platform that helps patients and physicians discover and access treatments in development. It charges pharmaceutical companies for its services in assisting with clinical trials, but for patients and physicians its services are free. With a model based on encouraging reciprocity, myTomorrows is looking to disrupt this market in a holistic way - changing things for the better and benefitting all sides.
With over 5000 patients helped, 500+ physician partners onboard, and access to over 300,000 clinical research studies, myTomorrows has managed to generate some impressive early metrics. This has attracted big investor interest, and myTomorrows is planning on using new funding to invest in new technology and increase its headcount.
In terms of market trends, the 'right to try' debate is still fierce across the world, but the shift in the last 20 years has clearly been towards liberalisation, especially in the US. It looks, then, like myTomorrows' prospects are going to get even stronger in the coming years.
Kirsty
Company Specialist at Welcome to the Jungle
Funding (last 2 of 4 rounds)
Jan 2017
$10.6m
SERIES A
Oct 2014
$4.8m
SEED
Total funding: $21.3m
This company has top investors
Leadership
Ronald Brus
(CEO)A physician by trade, Ronald is also the co-founder and CBO of Leyden Labs, and spent over 14 years at biotech company Crucell.
Diversity, Equity & Inclusion at myTomorrows
- MyTomorrows is an Equal Opportunity Employer and, beyond upholding discrimination-free practices, we are committed to cultivating a workplace where difference and diversity are protected and celebrated
Articles
Jobs (5)
Software Engineering
Marketing